SNMMI is a global and collaborative scientific organization dedicated to both the practice and the science of nuclear medicine and molecular imaging and therapy around the world. SNMMI's worldwide membership totals more than 17,000, including physicians, scientists, technologists, chemists, radiopharmacists, students and industry representatives from 76 countries around the world.
Access to 100 of the premier sessions from the SNMMI 2016 Annual Meeting! Learn more.
SNMMI is a global and collaborative scientific organization dedicated to both the practice and the science of nuclear medicine and molecular imaging and therapy around the world. SNMMI's worldwide membership totals over 18,000, which includes physicians, scientists, technologists, chemists, radiopharmacists, students and industry representatives from more than 75 countries around the world. SNMMI's Journal of Nuclear Medicine (JNM), the premier international journal of nuclear medicine, reaches over 18,000 individuals each month. SNMMI's Annual Meeting is nuclear medicine's and molecular iamging's largest gathering each year, attracting over 4,000 professional attendees and another 2,500 industry representatives.
At the most recent Annual Meeting in June 2013 in Vancouver, BC, Canada, 38% of registered attendees were from countries other than the United States. Attendees represented over 69 countries. In addition, abstract submissions for SNMMI's Annual Meeting from outside the United States represent close to 65% of all submissions.
While SNMMI's headquarters office resides in Virginia, just outside of Washington, D.C., its perspective, programs, and growth are as international as its members. As of 2013, more than 11.8% of the Society's members reside in more than 75 countries other than the United States.
Search for an international nuclear medicine and molecular imaging organization near you.
SNMMI's educational programs and activities reflect the increasing importance and participation of its international members. Such common global nuclear medicine and molecular imaging and therapy issues as quality of care, educating referring physicians and patients, and exploring ways to better share developments in the practice of nuclear medicine and molecular imaging and therapy are but a few of the activities currently underway by Society staff, Committees, Councils, and our Centers of Excellence. This website seeks to constantly expand its offerings to the Society's international members, providing an ever-changing, updated array of global resources and news for nuclear medicine and molecular imaging and therapy professionals literally anywhere on the globe.
SNMMI continues to stay actively involved in several jointly sponsored educational programs and educational outreach activities with regional nuclear medicine and molecular imaging and therapy organizations around the world; both in their home countries, and during SNMMI's Annual Meeting. These joint sponsored programs include not only the sharing of speakers and renown experts on all facets of nuclear medicine and molecular imaging, collaboration on the development of enduring educational materials, and programmatic/administrative support, but also include translation of materials and website development.
Each year, the SNMMI collaborates with international organizations in an effort to continue the exchange of ideas, education and knowledge. Intiatives include:
Nuclear Medicine Global Initiative
3rd Sino-American Conference
Chinese/U.S. Resident Exchange Program
IAEA CT Case Webinar Series
EANM Collaborative Guidelines
SNMMI offers a Full International Membership category for inernational colleagues. Learn more on how to become an SNMMI Full Member (international).
Available to physicians, scientists or pharmacists possessing an advanced degree who have presented credentials indicating their professional activity, either, medical, paramedical, investigational or educational in the scientific or clinical disciplines of molecular imaging or nuclear medicine. This includes the diagnostic, therapeutic or investigational use of radionuclides or other molecular imaging technologies.
Annual dues: $510
Includes subscription to The Journal of Nuclear Medicine.
Includes voting rights and can be elected an Officer of the SNMMI.
As part of its continuing commitment to growing the practice of nuclear medicine and molecular imaging and therapy worldwide, SNMMI leadership works diligently to develop strategic alliances with key regional nuclear medicine organizations to assist these groups in expanding the scope and quality of nuclear medicine outside the United States. These strategic alliances stretch across the globe. reaching every continent where SNMMI's members reside and practice.
SNMMI Partners and Alliances Include:
For more information on SNMMI's international activities and programs, please contact:
Nikki Wenzel-Lamb, MBA Director of Leadership Direct: 703-652-6766 Fax: 703-708-9020 Email: email@example.com
In nuclear medicine, the goal is to keep radiation exposure at a minimum, while obtaining quality images. Optimal dosing for individual patients can be difficult to determine. That’s where 3D-printed organ models of varying size and shape could be of great use. In a study reported in the December issue of "The Journal of Nuclear Medicine," researchers at the University of Würzburg in Germany focused on kidneys to demonstrate that low-cost 3D printing techniques can be used for quantitative SPECT/CT imaging.
New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer, even in areas where detection has previously been difficult. Published in the December issue of "The Journal of Nuclear Medicine," the Phase 1 dose-escalation study of Zr-89-desferrioxamine-IAB2M (Zr-89-Df-IAB2M), an anti-PSMA minibody, in patients with metastatic prostate cancer shows its effectiveness in targeting both bone and soft tissue lesions.
Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December issue of "The Journal of Nuclear Medicine."
(MI: Making a Difference)
On Wednesday, November 30, the House passed the 21st Century Cures legislation 392-26, sending the sweeping FDA and CMS reform package to the Senate.
(Government Relations News)
Explore the amazing research displayed at the SNMMI 2016 Annual Meeting.
SNMMI is continuing to highlight abstract presentations featured at the recent 2016 Annual Meeting with ePosters, a virtual online poster hall.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.
Happy Nuclear Medicine Week! Encourage community members to take pride in their profession – recognizing their colleagues for their hard work and promoting nuclear medicine to the entire medical community as well as to the public.